NCT01656811View on ClinicalTrials.gov

A Study of Daily Dosing With Levalbuterol, Racemic Albuterol, and Placebo in Pediatric Subjects With Asthma

PHASE2CompletedINTERVENTIONAL
Enrollment

146

Participants

Timeline

Start Date

October 31, 2001

Primary Completion Date

July 31, 2002

Study Completion Date

July 31, 2002

Conditions
Asthma
Interventions
DRUG

levalbuterol 90 mcg

90 mcg levalbuterol delivered via MDI 2 actuations of 45 mcg QID

DRUG

levalbuterol 180 mcg

180 mcg levalbuterol delivered via MDI 2 actuations of 90 mcg QID

DRUG

racemic albuterol 180 mcg

180 mcg racemic albuterol delivered via MDI 2 actuations of 90 mcg QID

DRUG

Placebo

Placebo 2 actuations QID

All Listed Sponsors
lead

Sumitomo Pharma America, Inc.

INDUSTRY

NCT01656811 - A Study of Daily Dosing With Levalbuterol, Racemic Albuterol, and Placebo in Pediatric Subjects With Asthma | Biotech Hunter | Biotech Hunter